Myocardial Viability Assessment

This section’s acute MI page introduced stunned and hibernating myocardium as two conditions that resting echocardiography genuinely cannot tell apart — both simply show reduced regional function at the moment imaging is performed. This page covers how to actually distinguish them, and — just as importantly — what the current trial evidence says about whether doing so changes outcomes.

Two Mechanisms, Both Reversible, Through Different Routes

Myocardial stunning describes a segment that suffered an acute ischemic insult, with blood flow subsequently restored — the myocardium is genuinely “alive” and will recover its contractile force unless another ischemic insult occurs. This classically applies to acute coronary syndromes with rapid reperfusion, but a chronic variant — repetitive stunning — occurs when a segment has preserved resting blood flow but critically reduced flow reserve, producing recurrent ischemic episodes with cumulative chronic dysfunction.

Myocardial hibernation describes a more chronic process: a critical reduction in resting myocardial blood flow itself, with systolic function adaptively reset to match that reduced supply — a steady state of matched perfusion and function that keeps the myocyte genuinely alive, just functionally quiescent.

Both mechanisms are reversible with successful revascularization, but through genuinely different routes: restoring flow reserve resolves repetitive stunning by abating the recurrent ischemic episodes driving it, while restoring resting flow itself resolves hibernation directly. This distinction is worth holding in mind conceptually, even though both ultimately present with the same resting finding — reduced regional function that clinical and ECG criteria alone cannot reliably classify, which is exactly why dedicated viability testing exists.

A First Pass: What Resting Echocardiography Alone Can Tell You

Before reaching for dedicated viability testing, resting echocardiographic appearance can identify segments unlikely to recover without any further testing: a segment that is akinetic or dyskinetic, thinned (under 5 mm of wall thickness), and hyperechogenic (bright) is very likely scarred and unable to recover function regardless of revascularization — the same thin, bright, dyskinetic appearance that defines a true LV aneurysm on that page’s own diagnostic criteria. Only in the absence of these features does dedicated viability testing become genuinely necessary — dobutamine echocardiography, myocardial strain, or contrast perfusion imaging, each distinguishing scar from viable but dysfunctional myocardium through a different biological mechanism.

Dobutamine Echocardiography: The Primary Echo Technique

Dobutamine echocardiography (DE) — evaluating the contractile response to incremental intravenous dobutamine infusion — is the most widely used and accepted echocardiographic technique for viability detection.

Protocol

2D images are obtained in the parasternal long- and short-axis views and the apical four- and two-chamber views, visualizing all segments at rest and through incremental dobutamine doses — starting at 2.5 or 5 µg/kg/min and increasing to 20, and up to 40 µg/kg/min, in 3- to 5-minute stages.

Starting at a genuinely low dose is critical: at low doses, dobutamine’s inotropic effect is more prominent than its chronotropic effect, allowing contractile response to be assessed without the tachycardia that higher doses can produce — tachycardia that could itself provoke ischemia and blunt or mask the very response being sought. Dobutamine’s short half-life (2–3 minutes) and negligible β2-receptor effect further explain why it’s specifically preferred for viability assessment over other agents.

Interpreting the Contractile Response

Segmental wall motion and thickening are graded at baseline and at each infusion stage, using the same normal/hypokinetic/akinetic/dyskinetic scale introduced on the LV Systolic Function page, applied to the same 17-segment map used for coronary territory localization. Segments with normal baseline contractility are considered viable by definition. For segments with baseline dysfunction, viability is determined by the pattern of response to inotropic stimulation:

• Biphasic response — improvement at low doses, followed by worsening at higher doses — viable, and the single pattern with the highest accuracy for predicting functional recovery after revascularization.
• Sustained improvement — improvement at low doses, without subsequent worsening — viable.
• A pattern of worsening contractility in a segment with resting hypokinesis, without initial improvement — still considered viable in the standard classification framework, reflecting genuine contractile responsiveness even when that response isn’t initially favorable.
• No appreciable change in contraction or thickening at any dose — not viable.

A patient is considered to have clinically significant viability when five or more segments, using a 16-segment model, are classified as viable — a specific, actionable threshold worth applying consistently rather than reporting viability only qualitatively.

Other Echocardiographic Techniques

Contrast echocardiography, while not a direct viability measure itself, improves wall motion assessment and can enhance the performance of a standard DE protocol — see Contrast Echocardiography for the general technique. Myocardial contrast perfusion imaging has also been proposed as a standalone viability method, using ultrasound-enhancing agents with specific low-mechanical-index settings, though its clinical use has remained limited in practice.

Myocardial strain quantifies global and segmental systolic function and has been proposed to improve sensitivity over standard B-mode wall motion grading for viability detection — but genuinely limited data currently support its routine use for this specific purpose, worth stating honestly rather than overselling a promising but not yet fully validated application.

No Modality Is Simply “Better” — Each Measures Something Different

Dobutamine echocardiography, nuclear perfusion and metabolic imaging (PET, SPECT), and cardiac MRI with late gadolinium enhancement all identify viability through genuinely distinct biological mechanisms, which explains real, consistent differences in their pooled sensitivity and specificity rather than one method simply outperforming another:

Technique	Sensitivity	Specificity
Dobutamine echocardiography (overall)	80%	78%
Low-dose dobutamine echocardiography	79%	78%
High-dose dobutamine echocardiography	83%	79%
Myocardial contrast echocardiography	87%	50%
Thallium-201 scintigraphy	87%	56%
PET	92%	63%
CMR (overall)	80%	70%
CMR with low-dose dobutamine	74%	82%
CMR with late gadolinium enhancement	84%	63%

The genuinely important pattern worth understanding, not just memorizing: nuclear imaging shows higher pooled sensitivity (90%) but lower specificity (57%) compared with dobutamine echocardiography’s higher specificity (78%) but lower sensitivity (74%) in head-to-head data. This isn’t coincidental — DE requires a relatively preserved contractile apparatus to produce a detectable response, inherently raising its specificity at some cost to sensitivity, while thallium scintigraphy only requires membrane integrity, a genuinely lower threshold that increases sensitivity at the cost of specificity. Choosing a modality — or interpreting discordant results across modalities — benefits from understanding this trade-off directly, rather than treating one number as simply “more accurate” than another.

The Current, Honest Trial Evidence: Does Viability Testing Actually Change Outcomes?

This is worth addressing directly rather than leaving implicit, since it genuinely shapes how viability testing should be used in practice. Retrospective studies have consistently associated viable myocardium with clinical benefit from revascularization, forming the traditional basis for viability-guided treatment decisions. But prospectively designed trials testing this hypothesis directly have consistently failed to confirm it.

• PARR-2 randomized 430 patients with suspected ischemic cardiomyopathy to a PET-assisted revascularization strategy versus standard care — showing only a non-significant trend toward fewer cardiac events.
• STICH similarly failed to demonstrate that viability assessment identified patients who preferentially benefited from revascularization.
• REVIVED-BCIS2, the most recent and largest such trial, randomized 700 patients with EF 35% or less, extensive CAD amenable to PCI, and viability in at least four dysfunctional segments, to PCI plus guideline-directed medical therapy versus guideline-directed therapy alone. Over 3.4 years of follow-up, PCI showed no significant reduction in the composite endpoint of death or heart failure hospitalization, and no incremental improvement in LV function beyond medical therapy alone — only slight, temporary symptomatic improvement.

A pre-specified secondary analysis of REVIVED-BCIS2 is genuinely worth knowing in detail: in 87% of trial patients, there was no significant correlation between the extent of viability (assessed by CMR or dobutamine stress echocardiography) and outcomes — a finding that directly challenges the traditional concept that hibernating myocardium reliably recovers with revascularization. However, the same analysis found that a larger amount of non-viable myocardium was independently linked to worse outcomes, regardless of whether PCI was performed — suggesting viability assessment may retain genuine value for risk stratification, even though it hasn’t been shown to reliably predict who specifically benefits from revascularization.

The practical takeaway worth stating plainly: viability testing remains a well-established, technically sound part of the workup for ischemic cardiomyopathy — functionally overlapping with, though mechanistically distinct from, dilated cardiomyopathy — and the techniques on this page are genuinely accurate at what they measure — distinguishing scar from living, dysfunctional myocardium. What current, high-quality prospective evidence does not support is the assumption that finding viability reliably identifies patients who will benefit from revascularization specifically. Both things can be true at once, and a good report reflects that honestly rather than treating “viable” as synonymous with “will recover with PCI.”

How to Approach Viability Assessment: A Practical Sequence

1. Start with resting 2D appearance — akinesis or dyskinesis with thinning and hyperechogenicity suggests scar strongly enough that further testing may add little for that specific segment.
2. Proceed to dobutamine echocardiography for segments without those features, following the low-start, graded-dose protocol, and classify each segment’s response pattern explicitly rather than simply noting “improved” or “didn’t improve.”
3. Apply the five-segment threshold (16-segment model) to determine whether a patient has clinically significant viability overall, not just whether any single segment responded.
4. Consider the specific modality’s sensitivity-specificity trade-off when interpreting results, especially when correlating with nuclear or CMR findings obtained elsewhere in the same patient’s workup.
5. Communicate findings with the current evidence in mind — report viability extent as a genuinely useful descriptive and risk-stratifying finding, while being honest that it hasn’t been shown to reliably predict revascularization benefit in the most recent, largest prospective trial.

Clinical Importance

Viability assessment is the clearest example in this entire section of a technique that is simultaneously well-validated and genuinely contested — the dobutamine protocol, the response patterns, and the modality trade-offs described here are established, reproducible, and clinically used every day, while the actual clinical question that motivated developing them — does finding viability mean a patient will benefit from revascularization — remains genuinely unresolved by the best current trial evidence. Holding both of those facts together, rather than defaulting to either uncritical enthusiasm or dismissal, is what this page is ultimately about.